Scarica l'app Stockscreener
7.80
0.00%
0.00
Dopo l'orario di chiusura:
7.88
0.08
+1.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$7.80
Aprire:
$7.71
Volume 24 ore:
55,358
Relative Volume:
0.95
Capitalizzazione di mercato:
$53.04M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.3028
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
+9.24%
1M Prestazione:
+3.86%
6M Prestazione:
-35.93%
1 anno Prestazione:
-45.09%
Intervallo 1D:
$7.4419
$7.88
Intervallo di 1 settimana:
$7.20
$8.0999
Portata 52W:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.80 | 42.56M | 100.44M | -133.16M | -94.85M | -25.76 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com
(ATRA) Trading Advice - news.stocktradersdaily.com
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace
Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks
(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com
Atara Biotherapeutics Announces $16M Stock Offering - TipRanks
Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider
Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics (ATRA) Announces $16M Share Offering - GuruFocus
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics sets stock and warrant offering prices - Investing.com
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering - GuruFocus
Atara Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces Major Workforce Reduction - TipRanks
Atara Biotherapeutics To Reduce Workforce By 30% - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
FDA lifts clinical hold on Atara’s Ebvallo - The Pharma Letter
FDA Lifts Hold on Atara’s EBVALLO Program - TipRanks
Atara Does An About Face As FDA Lifts Ebvallo Hold - insights.citeline.com
(ATRA) Investment Analysis - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth - simplywall.st
Atara Biotherapeutics Says FDA Lifts Clinical Hold on Ebvallo Investigational New Drug Applications - marketscreener.com
FDA Lifts Hold on Atara Biotherapeutics' Ebvallo Program | ATRA Stock News - GuruFocus
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | ATRA Stock News - GuruFocus
Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials - marketscreener.com
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire
Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO?? (Tabelecleucel) - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):